Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60)
Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
Mild/Moderate ( n =30) (absence of severe criteria)

Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60)
Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia)
Mild/Moderate ( n =30) (absence of severe criteria)

Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80)
Asthma (defined as severe) - (n=20)
CF (FEV1% predicted baseline <50%) - (n=20)
COPD (FEV1% predicted baseline <50%) - (n=20)
Idiopathic Pulmonary Fibrosis (n=20)

Spontaneously expectorated sputum, nasal lavage, brushings and nasal synthetic absorptive matrix (SAM) samples Venous blood (60mls) will be taken into Lithium Heparin tubes and PAXgene RNA tubes PAXgene tubes will be stored at -80C for further host genetic sequencing analysis. Further immunological analysis using yeast surface display for serum antibody profiling, single B cell sorting to generate monoclonal antibodies and ELISPOT to analyse CD4 and CD8 T cell ELISPOT to SARS CoV-2 peptide pools.

COVID-19

SARS-CoV 2

ARDS, Human

Immune System Disorder

Venesection, sputum nasal lavage and brushing if appropriate

Blood tests sputum, nasal lavage and brushing

PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort

Anti-viral cytokine protein concentration in blood samples by ELISA

Inflammatory cytokine protein concentration in sputum samples by ELISA

Inflammatory cytokine protein concentration in nasal lavage samples by ELISA

Inflammatory gene expression in upper airway respiratory epithelial cells by RNA sequencing.

Analysis of viral components recognized by the adaptive immune system

Cytokine protein concentration following PBMC stimulation to pathogen recognition receptor agonists by Elispot

Serum and plasma protein concentration of endothelial cell inflammation biomarkers by ELISA

Imperial College London

Royal Brompton & Harefield NHS Foundation Trust

Chelsea and Westminster NHS Foundation Trust

Imperial College Healthcare NHS Trust

Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year

400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year

Pulmonary Emphysema

Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution

Mesenchymal stem cells

Reference therapy: 400 mL of 0.9% NaCl solution

Federal Research Clinical Center of Federal Medical and Biological Agency of Russia

Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema

Mortality (Baseline and 2 years after procedure) Adverse effects and reactions to the treatment(Baseline and 2 years after procedure).
Vital signs (pulse rate, systolic and diastolic arterial blood pressure) (Baseline and 2 years after procedure)

elastase/hypoxia

PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort

Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema

Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne